Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 600x60px
Document › Details

Calliditas Therapeutics AB. (11/15/17). "Press Release: Pharmalink Is Renamed Calliditas Therapeutics".

Organisations Organisation Calliditas Therapeutics AB
  Organisation 2 Optimum Strategic Communications
Products Product Nefecon®
  Product 2 public relations / investor relations (services)
Index term Index term Calliditas Therapeutics–Optimum Strategic Communications: public relations, 201711 service existent by Optimum
Persons Person Aguiar-Lucander, Renée (Pharmalink AB 201708 CEO)
  Person 2 Widell, Mikael (Pharmalink AB 201708– Head of Communications before Cord Communications + Nordic Capital)

The specialty pharmaceutical company Pharmalink AB today announced that it has changed its name to Calliditas Therapeutics AB (“Calliditas Therapeutics” or the “company”).

The Swedish Companies Registration Office has approved and registered the company's change of name from Pharmalink AB to Calliditas Therapeutics AB. More information about Calliditas Therapeutics and its clinical projects can be found on the new website

For further information, please contact:

Calliditas Therapeutics AB
Renée Aguiar-Lucander, Chief Executive Officer
Mobile: +46 (0)72 252 1006

Mikael Widell, Head of Communications
Mobile: +46 (0)70 311 9960

Optimum Strategic Communications
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 (0)203 714 1787

Notes to editors

About Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company focused on developing high value medical products for patients with significant unmet medical needs in niche indications. Calliditas Therapeutics is focused on the development and commercialization of its lead product candidate, Nefecon, which has successfully completed a Phase 2b clinical study as a potential new treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Backed by a strong investor base with a clear long-term vision and a track record of bringing products to the market, Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. In addition, the company has identified other potential uses of Nefecon in niche indications, and will investigate the development of these to provide new treatments for patients with unmet medical needs.

Visit for further information.

Calliditas Therapeutics AB
Wallingatan 26B
SE-111 24 Stockholm

Company number: 556659-9766

Record changed: 2017-11-26


Picture [LSG] – The Business Web Portal 600x80px

More documents for Calliditas Therapeutics AB

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

» top


Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px